

# Long-primed germinal centres with enduring affinity maturation and clonal migration

<https://doi.org/10.1038/s41586-022-05216-9>

Received: 13 December 2021

Accepted: 9 August 2022

Published online: 21 September 2022

 Check for updates

Jeong Hyun Lee<sup>1,2,3,15</sup>, Henry J. Sutton<sup>1,2,15</sup>, Christopher A. Cottrell<sup>2,3,4</sup>, Ivy Phung<sup>1,2,5</sup>, Gabriel Ozorowski<sup>2,3,6</sup>, Leigh M. Sewall<sup>6</sup>, Rebecca Nedellec<sup>4</sup>, Catherine Nakao<sup>1</sup>, Murillo Silva<sup>2,7</sup>, Sara T. Richey<sup>6</sup>, Jonathan L. Torres<sup>6</sup>, Wen-Hsin Lee<sup>6</sup>, Erik Georgeson<sup>2,3,4</sup>, Michael Kubitz<sup>2,3,4</sup>, Sam Hodges<sup>2,3,4</sup>, Tina-Marie Mullen<sup>2,3,4</sup>, Yumiko Adachi<sup>2,3,4</sup>, Kimberly M. Cirelli<sup>1,2</sup>, Amitinder Kaur<sup>8</sup>, Carolina Allers<sup>8</sup>, Marissa Fahlberg<sup>8</sup>, Brooke F. Grasperge<sup>8</sup>, Jason P. Dufour<sup>8</sup>, Faith Schiro<sup>8</sup>, Pyone P. Aye<sup>8</sup>, Oleksandr Kalyuzhnyi<sup>2,3,4</sup>, Alessia Liguori<sup>2,3,4</sup>, Diane G. Carnathan<sup>2,9</sup>, Guido Silvestri<sup>2,9</sup>, Xiaoying Shen<sup>10</sup>, David C. Montefiori<sup>10</sup>, Ronald S. Veazey<sup>8</sup>, Andrew B. Ward<sup>2,3,6</sup>, Lars Hangartner<sup>2,4</sup>, Dennis R. Burton<sup>2,3,4,11</sup>, Darrell J. Irvine<sup>2,7,11,12,13,14</sup>, William R. Schief<sup>2,3,4,11</sup> & Shane Crotty<sup>1,2,5</sup>✉


Germinal centres are the engines of antibody evolution. Here, using human immunodeficiency virus (HIV) Env protein immunogen priming in rhesus monkeys followed by a long period without further immunization, we demonstrate germinal centre B ( $B_{GC}$ ) cells that last for at least 6 months. A 186-fold increase in  $B_{GC}$  cells was present by week 10 compared with conventional immunization. Single-cell transcriptional profiling showed that both light- and dark-zone germinal centre states were sustained. Antibody somatic hypermutation of  $B_{GC}$  cells continued to accumulate throughout the 29-week priming period, with evidence of selective pressure. Env-binding  $B_{GC}$  cells were still 49-fold above baseline at 29 weeks, which suggests that they could remain active for even longer periods of time. High titres of HIV-neutralizing antibodies were generated after a single booster immunization. Fully glycosylated HIV trimer protein is a complex antigen, posing considerable immunodominance challenges for B cells<sup>1,2</sup>. Memory B cells generated under these long priming conditions had higher levels of antibody somatic hypermutation, and both memory B cells and antibodies were more likely to recognize non-immunodominant epitopes. Numerous  $B_{GC}$  cell lineage phylogenies spanning more than the 6-month germinal centre period were identified, demonstrating continuous germinal centre activity and selection for at least 191 days with no further antigen exposure. A long-prime, slow-delivery (12 days) immunization approach holds promise for difficult vaccine targets and suggests that patience can have great value for tuning of germinal centres to maximize antibody responses.

Antibodies serve as effective adaptive immunity frontline defences against most infectious diseases. As such, most efficacious vaccines aim to prophylactically elicit potent neutralizing antibodies and long-lasting immunological memory to the target pathogen. For rapidly mutating pathogens such as human immunodeficiency virus (HIV) there is an extra level of complication wherein an ideal vaccine should generate cross-reactive or broadly neutralizing antibodies that can protect against variants<sup>3,4</sup>; however, so far, no broadly neutralizing antibodies against HIV have been elicited in the serum of either humans or non-human primates (NHPs) by vaccination<sup>2</sup>.

High-affinity antibodies are typically the result of affinity maturation in germinal centres (GCs). GCs represent evolution in miniature, with proliferation (generations) accompanied by mutations and competition for limiting resources in the form of antigen and T cell help<sup>5–8</sup>. To

accomplish this evolution, GC B cells ( $B_{GC}$  cells) proliferate rapidly—every 4–6 h<sup>9,10</sup>. GCs are often observed for a few weeks following acute antigen exposure. Antigen-specific  $B_{GC}$  cells have been widely observed for 14–28 days in most model systems, and such a time window can represent a substantial amount of antibody sequence space exploration by  $B_{GC}$  due to their rapid cell cycle<sup>5,8</sup>. We previously showed that vaccine slow-delivery methods over a period of 7–14 days, such as the use of osmotic pumps or repeated small-dose injections, enhanced immune responses relative to traditional bolus immunizations<sup>11–13</sup>, with some evidence of increased durability of GCs for 2 months<sup>13</sup>. However, the full potential longevity of GCs, the biological programming of long-lasting GCs, antibody maturation under such conditions and the functionality and productivity of older GCs are minimally understood. Here, we used a 12 day, slow-delivery protein immunization strategy

A list of affiliations appears at the end of the paper.



**Fig. 1 | GCs after priming immunization can last for more than 6 months.** **a**, Experimental schematic. **b, c**, Quantification of B<sub>GC</sub> cell kinetics. Triangles below indicate primary and booster immunizations. **b**, Quantification of total B<sub>GC</sub> cells as a percentage of total CD20<sup>+</sup> B cells. **c**, Env-binding B<sub>GC</sub> cells as a percentage of total B cells. LOD, limit of detection. **d**, Representative flow cytometry plots of Env-binding B<sub>GC</sub> cells from left ILN of one long-prime group 3

animal over time. Red outline indicates post booster; gated on CD20<sup>+</sup>/CD71<sup>+</sup>CD38<sup>-</sup> B<sub>GC</sub> cells. Mean and s.d., or geometric mean and geometric s.d., are plotted depending on the scale in all figures unless otherwise stated. Left and right ILNs are graphed as independent data points (group 1, *n* = 12; groups 2 and 3, *n* = 8).

and antigen-specific molecular and cellular tools to explore the extent of GC durability after priming immunization, and the ensuing immunological outcomes.

### Priming can fuel GCs for several months

Alum is a classic adjuvant used in many human vaccines<sup>14</sup>. A group of rhesus monkeys (RMs) were given bolus injections of recombinantly expressed stabilized HIV Env trimer MD39 (ref.<sup>15</sup>) formulated with alum adjuvant (50 µg of protein and 500 µg of alhydrogel adjuvant per side), reflective of how most licensed human protein vaccines are formulated and administered as a bolus (group 1) (Fig. 1a). In an effort to generate more robust GCs, we immunized two groups of RMs with MD39 Env trimer formulated with the new immune-stimulating complex-type adjuvant saponin/MPLA nanoparticle (SMNP)<sup>16</sup> (groups 2 and 3) (Fig. 1a). Priming immunization for these two groups was administered via a slow-delivery vaccination method termed escalating dose<sup>11</sup>, in which the total dose of MD39 plus SMNP formulation (50 µg of protein and 375 µg of adjuvant per side) was split between seven gradually increasing doses, delivered every other day for a total of 12 days (Extended Data Fig. 1a). Group 3 was designed with an unusually long prime period to assess the durability of GCs after primary immunization. Each animal in the study was immunized bilaterally, thereby doubling the number of lymph nodes (LNs) and GCs that could be tracked over time. GCs were sampled every 2–3 weeks by fine-needle aspiration (FNA)<sup>17</sup> of inguinal LNs (ILNs) (Fig. 1a).

After priming immunization, conventional MD39 plus alum bolus-immunized monkeys (group 1) exhibited an increase in total B<sub>GC</sub> cell (CD71<sup>+</sup>CD38<sup>-</sup>) percentage at week 3 post immunization (Fig. 1b); the frequency of Env-binding B<sub>GC</sub> cells (CD71<sup>+</sup>CD38<sup>-</sup> Env<sup>+/+</sup>) peaked at week 3 and declined thereafter (Env-binding B<sub>GC</sub> cells as percentage of total B cells) (Fig. 1c). Both total and Env-binding B<sub>GC</sub> cells were substantially increased in MD39 plus SMNP ED-immunized RMs compared with those that received conventional protein plus alum bolus immunization (Fig. 1b,c and Extended Data Figs. 1b,c and 2a). Median peak B<sub>GC</sub> cell frequencies observed were 24–33% compared with 3.5% (*P* < 0.0001 by Mann–Whitney, week 3 groups 2 and 3 combined versus group 1; Fig. 1b). Median Env-binding B<sub>GC</sub> cell frequencies were around 7.8-fold greater at week 3 (*P* < 0.0025 by Mann–Whitney, groups 2 and 3 combined versus group 1) (Fig. 1c). Strikingly, in contrast to the conventionally primed group 1, frequencies of Env-binding B<sub>GC</sub> cells in groups 2 and 3 continued to increase, resulting in a 186-fold GC difference


by week 10 (*P* < 0.0001 by Mann–Whitney, groups 2 and 3 combined versus group 1) (Fig. 1c).

Tracking of priming immune response continued for group 3 monkeys beyond week 10 (group 1 and 2 monkeys were boosted at week 10) (Fig. 1a). GC responses were still active at weeks 13, 16, 21, 25 and 29 (Fig. 1b–d and Extended Data Fig. 2a,b). In group 2, the geometric mean fluorescent intensity of MD39 binding continued to increase beyond week 10, suggesting that MD39-specific B<sub>GC</sub> cells continued to gain affinity in the absence of a booster (Extended Data Fig. 2c). Env-binding B<sub>GC</sub> cell frequencies at week 29 were still 27-fold higher than the peak observed after conventional alum immunization, and they were also greater than the booster response to conventional alum immunization (Fig. 1c). At 191 days (27 weeks) after the end of the priming dose (29 weeks from day 0), median Env-binding B<sub>GC</sub> cell frequencies in ILNs were still around 49-fold higher than baseline (Fig. 1b–d and Extended Data Fig. 2a,b). Thus, GCs were present for more than 191 days with no further antigen introduced.

GC-T follicular helper (T<sub>FH</sub>) cells have a critical role in the recruitment and selection of B<sub>GC</sub> cells<sup>6</sup>. Total frequencies of GC-T<sub>FH</sub> cells in ILNs changed over the course of the priming period (Extended Data Fig. 2d). Env-specific GC-T<sub>FH</sub> cell frequencies were higher in group 3 after booster (Extended Data Fig. 2e,f)<sup>18</sup>; longitudinal quantitation was not possible due to the limiting availability of FNA samples. Long-lasting prime GCs may contribute to an improved antigen-specific GC-T<sub>FH</sub> response following booster immunization.

### Enhanced antibody response quality

The Env-binding serum IgG titres of group 3 RMs remained stable from weeks 3 to 29 of the priming phase in the absence of a booster immunization (Fig. 2a). After boosting, group 2 and 3 monkeys generated similar peak binding antibody titres (2–3 weeks post booster) but group 3 monkeys maintained significantly higher Env-binding IgG titres at week 6 after the booster (Fig. 2b). The quality of the antibody response was evaluated for the ability to neutralize autologous tier-2 BG505 pseudovirus. Notably, autologous tier-2 neutralizing antibodies were detectable in all long-prime group 3 monkeys after only the priming immunization (geometric mean titre (GMT) about 170 at week 29) (Fig. 2c). All monkeys receiving escalating-dose immunization generated robust neutralizing antibody responses post booster (Fig. 2c,d); by contrast, only a single animal with conventional bolus immunization had detectable autologous neutralizing



**Fig. 2 | Long priming enhances antibody quality.** **a**, Env-binding serum IgG endpoint titres (ETs). **b**, Env-binding IgG titres following booster; triangles indicate the booster time point. **c, d**, BG505 HIV pseudovirus neutralization titres at 50% inhibition (ID<sub>50</sub>). Comparison of post-booster neutralization GMTs (d). GMT with geometric s.d. from four independent repeats, with duplicate wells per assay. **b, d**, Two-sided Mann-Whitney test was performed. **e**, Heterologous tier-2 virus neutralization titres. GMT with geometric s.d. from four independent repeats, with duplicate wells per assay. **f**, Heterologous tier-2

viruses neutralized (ID<sub>50</sub> > 50) in the 12-virus global panel, after booster. Virus names are abbreviated (Methods). **g**, EMPEM of polyclonal plasma Fabs post booster. Group 1 at week 2 post booster; groups 2 and 3 at week 3 post booster; Env trimer is shown in grey. Fab colours coded as per epitope (**h**). **h**, Epitope sites recognized by EMPEM (**g**) for each animal (six possible sites per animal), tabulated for each animal group. Fisher's exact test comparing epitopes recognized versus those not recognized between groups. Group 1, *n* = 6; groups 2 and 3, *n* = 4. \*\**P* < 0.01.

antibodies, which were of low titre (around 37) (Extended Data Fig. 3a). Peak observed autologous neutralizing GMTs in group 3 were all more than 2,000 (week 3 post booster) (Fig. 2c). Group 3 autologous neutralization titres were fourfold greater than those of group 2 at 6 weeks post booster (Fig. 2c,d). The titres described represent the most robust and consistent autologous tier-2 neutralizing antibody responses in RMs after two immunizations in any of our studies<sup>12,13,16</sup>.

Group 2 and 3 post-booster sera exhibited some of the broadest-observed tier-2 neutralizing antibody specificities elicited by Env trimer immunization, with most monkeys from group 3 exhibiting greater breadth than those in group 2 (Fig. 2e,f). The 12-virus global neutralization panel was repeated by an independent laboratory, with similar observation of neutralization breadth (Extended Data Fig. 3b,c). In head-to-head assays, limited tier-2 neutralization breadth was observed with serum from a previous RM study with escalating-dose immunization and two booster immunizations using a similar Env trimer (Olio6) and an earlier immune-stimulating complex adjuvant (SMNP without MPLA)<sup>13</sup> (Extended Data Fig. 3d,f–h), and likewise for serum from an RM study with three bolus immunizations of MD39 Env trimer and SMNP (Extended Data Fig. 3e–h)<sup>16</sup>.


Most of the HIV Env-binding B cells and antibodies are usually directed to immunodominant non-neutralizing epitopes, such as the base of soluble recombinant Env trimers<sup>1,13,19–21</sup>. Electron microscopy polyclonal epitope mapping (EMPEM)<sup>21</sup> of circulating antibodies showed that the number of targeted epitopes was significantly increased in groups 2 and 3 than in group 1 (*P* = 0.0066) (Fig. 2g,h and Extended Data Fig. 4), which correlated with autologous neutralizing titres (Fig. 2c (post booster) and Extended Data Fig. 3a). Group 2 and 3 monkeys generated antibody responses to V5/C3 and V1/V3 epitopes (Fig. 2g,h) associated with autologous BG505 SHIV protection<sup>22</sup>. Antibody responses in conventional bolus-plus-alum-immunized monkeys were largely restricted to the Env trimer base (Fig. 2g,h). In summary, the priming immunization strategy used was associated with substantially improved epitope breadth and quality of neutralizing antibodies.

## Six month B<sub>GC</sub> cells are highly functional

The characteristics of B<sub>GC</sub> cells after priming were interrogated in greater detail to assess their functionality over time. BCL6 is the lineage-defining transcription factor of B<sub>GC</sub> cells and is essential for their functionality<sup>7</sup>. KI67 (encoded by *MKI67*) marks rapidly dividing cells. LN B cells from months 5 to 6 (weeks 21–25) were stained for BCL6 and KI67 protein. On average, about 72% of Env-binding CD71<sup>+</sup>CD38<sup>-</sup> B<sub>GC</sub> cells were KI67<sup>+</sup>BCL6<sup>+</sup> (Fig. 3a,b and Extended Data Fig. 5), indicating retained B<sub>GC</sub> programming and proliferation. To further ascertain the phenotypic and functional characteristics of B<sub>GC</sub> cells at different time points, single-cell transcriptional profiling was done for about 70,000 cells from LN FNAs of weeks 3, 4, 7, 10, 13, 16, 29 and 33, predominantly consisting of Env-binding B<sub>GC</sub> cells as well as peripheral blood-sorted Env-binding memory B (B<sub>mem</sub>) cells from weeks 16 (group 2) and 36 (group 3). Dark-zone and light-zone cell clusters were clearly observed among LN B cells when analysing all time points together (Fig. 3c and Extended Data Fig. 6). We then examined B<sub>GC</sub> cell transcriptional profiles over the course of group 3 RM long priming period (weeks 3, 7, 16 and 29; Fig. 3d–h and Extended Data Fig. 6)<sup>23,24</sup>. Light- and dark-zone states were sustained across the 6 month period (Fig. 3d). Expression of key functional B<sub>GC</sub> genes *MKI67*, *AICDA*, *MYC* and *CD40* was maintained over time, and was compartmentalized comparably between dark- and light-zone cell types at all time points (Fig. 3e–h and Extended Data Fig. 6d). The ratio of dark-zone to light-zone cells remained relatively consistent over the course of the priming period (Fig. 3i). Overall, antigen-specific B<sub>GC</sub> cells possessed stable phenotypic characteristics over a 6 month period, indicative of long-term maintenance of functional B<sub>GC</sub> cell properties in the absence of further immunization.

## B<sub>GC</sub> cell receptor evolution lasts for months

To directly assess the functionality of GCs over these extended time periods, multiple experimental approaches were used comparing group 2 and 3 RMs. B cell receptor (BCR) sequencing of Env-binding LN FNA-derived B<sub>GC</sub> cells was performed from nine time points to assess



**Fig. 3 | B<sub>CC</sub> cell phenotypic and functional characteristics over the course of 6 months.** **a**, Representative flow cytometry gating showing CD71<sup>+</sup>CD38<sup>+</sup> and Ki67<sup>+</sup>BCL6<sup>+</sup> B<sub>CC</sub> cells (see Extended Data Fig. 5a for sample information). Back-gating of CD71<sup>+</sup>CD38<sup>+</sup> Ki67<sup>+</sup>BCL6<sup>+</sup> Env<sup>+/+</sup> B<sub>CC</sub> cells is shown in cyan. **b**, Frequency of Ki67<sup>+</sup>BCL6<sup>+</sup> cells among CD71<sup>+</sup>CD38<sup>+</sup> Env<sup>+/+</sup> B<sub>CC</sub> cells. **c**, Uniform manifold approximation and projection (UMAP) visualization of single-cell gene expression profiles identifying clusters of B cell states from LN FNAs and

peripheral blood mononuclear cells (PBMCs). **d**, Per time point UMAP plots extracted from **c**. **e–h**, Relative gene expression of *MKI67* (**e**), *AICDA* (**f**), *MYC* (**g**) and *CD40* (**h**) in dark-zone (DZ) and light-zone (LZ) subclusters representative of classical DZ and LZ phenotypes DZ5 and LZ1. Additional data given in Extended Data Fig. 6. **i**, The dark-zone to light-zone ratio, as determined by single-cell clustering in LNs after priming.

antibody somatic hypermutation (SHM) over time, as well as clonal diversity and mutational patterns in clonal lineages (Fig. 4 and Extended Data Figs. 7–10). Env-binding B<sub>CC</sub> cell heavy-chain (HC) nucleotide mutations increased significantly between weeks 3 and 10 ( $P < 0.0001$  by Mann–Whitney for groups 2 and 3; Fig. 4a,b). Notably, B<sub>CC</sub> cells continued to accumulate mutations in the absence of further immunization through to week 29 in group 3 RMs, at which point the median number of HC mutations was 17, with the top 25% of B<sub>CC</sub> cells containing 22–45 HC mutations (Fig. 4a,b). The difference in SHM in the long prime (week 29) versus 10 week prime was highly significant ( $P < 0.0001$  by Mann–Whitney, Fig. 4b;  $P < 0.0009$ , Fig. 4c), and the difference in median mutations between weeks 10 and 29 was as great as that between weeks 4 and 10, indicative of robust GC functionality continuing through to at least week 29 (Fig. 4a–c). The proportion of unmutated Env-binding B<sub>CC</sub> cells dropped over time, with 0.19–0.42% unmutated cells by week 7 (Fig. 4b). Substantial mutations were also observed in light chains (LC), with patterns comparable to HCs (Extended Data Fig. 7a–d). Env-binding B<sub>CC</sub> cells showed a gradual reduction in estimated clonal richness over time (Chao1) (Fig. 4d and Extended Data Fig. 7e), with sustained diversity (Simpson’s diversity index) (Extended Data Fig. 7f,g).


After booster immunization, HC mutations increased in Env-binding B<sub>CC</sub> cells of both group 2 and 3 RMs, with the highest overall number of mutations in long-primed RMs (week 3 post-booster HC median mutations 13 versus 20) (Fig. 4b,c and Extended Data Fig. 7c). Comparable observations were made for LC mutations (Extended Data Fig. 7d).

Pre-booster Env-binding B<sub>mem</sub> cell (CD20<sup>+</sup>IgD<sup>+</sup> Env<sup>+/+</sup>) frequencies in peripheral blood were equivalent in RMs from groups 2 and 3 (Fig. 4e and Extended Data Fig. 7h). Boosting increased Env-binding B<sub>mem</sub> frequencies in both groups (Fig. 4e). RMs with the long prime had more highly mutated B<sub>mem</sub> cells and greater clonal richness among B<sub>mem</sub> cells (Fig. 4f,g), with equivalent Simpson’s diversity indices (Extended Data Fig. 7i). This was also reflected in a significant shift away from immunodominant, base-binding, Env-specific B<sub>mem</sub> cells following boosting of the long-primed group, which was not seen in group 2 (Fig. 4h), and this phenomenon was also reflected in circulating antibody titres (Fig. 4i).

Clonal lineage analysis of paired BCR sequences was used to examine GC duration and functionality over several months after single immunization. Many clonal lineages were identified, with B<sub>CC</sub> clones observed

at the first and last LN FNA time points post prime and extensive SHMs between (Fig. 4j,k and Extended Data Figs. 8–10). Some clonal lineages were identified with B<sub>CC</sub> clones observed at every, or nearly every, LN FNA time point, providing direct evidence of B<sub>CC</sub> cell persistence over 29 weeks (Fig. 4j,k and Extended Data Figs. 8, 9 and 10a,c). Diversification of clones in clonal lineages was apparent. Daughter clones most evolutionarily divergent from the germline were typically present at late time points (mutations to time correlation: lineage 21094,  $R^2 = 0.72$ ,  $P < 0.001$ ; lineage 29121,  $R^2 = 0.68$ ,  $P < 0.001$ ) (Fig. 4j and Extended Data Figs. 8 and 9c,d).

For some lineages, such as 5491 and 29183, most early B<sub>CC</sub> cell clones did not bind Env by flow cytometry (Env<sup>-/-</sup>) but B<sub>CC</sub> clones from later weeks and B<sub>mem</sub> clones bound Env by flow cytometry (Env<sup>+/+</sup>), indicative of a clone that started with low affinity to Env and that subsequently matured (Extended Data Fig. 10a,b). To directly assess affinity maturation within these lineages, monoclonal antibodies from several time points in three large clonal lineages were generated. An early monoclonal antibody from lineage 20181 had relatively low affinity to MD39 (week 4, dissociation constant ( $K_d$ ) =  $2.19 \times 10^{-7}$  M). An increase in affinity of roughly 17-fold ( $K_d = 1.23 \times 10^{-8}$  M) was observed by week 16 and a further (roughly) twofold increase by week 29 ( $K_d = 6.52 \times 10^{-9}$  M), representing around a 30-fold overall increase in affinity (Extended Data Fig. 8a). In lineage 29121, the antibody with the lowest affinity at week 3 ( $K_d = 1.55 \times 10^{-6}$  M) used an HC identical to the amino acid sequence of the unmutated common ancestor (UCA) (Extended Data Fig. 8a). In this lineage, almost one-third of the cells found at week 3 did not bind MD39 via flow cytometry, including the UCA HC clone (Extended Data Fig. 8b), which indicates that this lineage started with a very weak affinity and was still able to participate substantially in the GC reaction. In the same lineage, antibodies were isolated at weeks 16 and 29 with affinities about 200-fold ( $K_d = 7.70 \times 10^{-9}$  M) and 950-fold ( $K_d = 1.63 \times 10^{-9}$  M) higher than the week 3 HC UCA clone (Extended Data Fig. 8a). Finally, a low-affinity lineage 21094 antibody (week 3,  $K_d > 1.00 \times 10^{-5}$  M; Env<sup>-/-</sup> by flow cytometry) had gained over a 1,000-fold improvement in affinity by week 29 ( $K_d = 9.55 \times 10^{-9}$  M,  $6.49 \times 10^{-9}$  M) (Extended Data Fig. 8a). Altogether, these data strongly support the conclusion that substantial affinity maturation occurs over the course of the 6 month priming period, leading in some cases to B<sub>CC</sub> cells with around 1,000-fold improved affinity.



**Fig. 4 | Antigen-specific B<sub>GC</sub> and B<sub>mem</sub> cell SHM and affinity maturation.**  
**a**, Nucleotide mutations in the V- and J-gene region of HC sequences derived from Env-binding B<sub>GC</sub> cells after priming; spaghetti plots track mutations per animal (*n* = 8). **b**, Pre-booster (lighter colour) and post-booster (darker colour) nucleotide mutations in Env-binding B<sub>GC</sub> cells. The median and quartiles are denoted by thick and dotted lines, respectively. **c**, B<sub>GC</sub> mutations at the last pre-booster time point and 3 weeks post booster. Two-way analysis of variance (ANOVA) multiple comparisons test. **d**, B<sub>GC</sub> clonal richness at post-prime time points (Chao1). **e**, Frequency of Env-binding B<sub>mem</sub> cells in blood. Two-way ANOVA multiple comparisons test. **f**, Clonal richness of B<sub>mem</sub> cells after

boosting (Chao1). **g**, HC mutations in week 6 post-booster B<sub>mem</sub> cells. **h**, Env-binding B<sub>mem</sub> cells that do not bind the trimer base. **i**, Serum ELISA titres of Env non-base-directed IgG. **b, f, g, i**, Two-sided Mann-Whitney test; **c, e, h**, two-way ANOVA multiple comparisons test. **j**, Representative clonal lineage trees from two group 3 monkeys (DHTT and L282), colour coded by time points (top) and Env binding (bottom). **k**, Clonal lineage 20181, colour coded by time point (top) and sample anatomical location (bottom). Clone 20181 has a 14-amino acid H-CDR3 with two or more N additions, and was represented by ten or more cells per LN. Each ring indicates five estimated HC nucleotide mutations from the most recent common ancestor.

B<sub>mem</sub> cells were commonly represented in clonal lineage trees among multiple sublineages, including among the most mutated branches observed at late LN FNA B<sub>GC</sub> time points (Fig. 4j, k and Extended Data Figs. 8, 9a, b and 10a), demonstrating that GCs productively output highly mutated B<sub>mem</sub> cells. Clonal lineages with other interesting features were observed among long-prime GCs, including lineage 21275, which was almost exclusively IgM from weeks 3 to 29 (Extended Data Fig. 10c).

There were clonal lineages with clones detected in both left and right ILN at different time points during the long-primed GCs (Fig. 4k and Extended Data Figs. 9a, b and 10b, c). Out of 169 clonal lineages passing stringent criteria (HC complementarity-determining region 3 (H-CDR3) length greater than 14, multiple N additions in H-CDR3, more than 20 cells in total and a matching LC), 11 lineages were observed in both LNs (ten or more cells per LN) at different time points, providing evidence that B<sub>mem</sub> cells generated from GCs in one LN can exit, recirculate and enter ongoing GCs in another LN. Using less restrictive criteria of clonal lineages containing at least five cells with H-CDR3 length greater than 10 and a matching LC, we observed that 54 out of 889 clonal lineages could be found in bilateral LNs (Extended Data Fig. 10f).

In summary, key features observed in numerous antigen-specific clonal lineages provide direct evidence of B<sub>GC</sub> cell persistence over 29 weeks, continuous accumulation of somatic mutations at substantial rates, affinity maturation, clonal migration and seeding of the peripheral B<sub>mem</sub> cell compartment which, together show that, under select conditions, GCs are able to undergo clonal evolution for extremely long durations without new antigen exposure.

### Discussion

Long-lasting GCs have classically been observed in the context of chronic infections and gut microbiota exposure<sup>25,26</sup>, conditions known to have continuous live sources of renewed antigen. Recent reports of longer-lasting GCs in influenza infection<sup>27</sup>, SARS-CoV-2 infection<sup>28</sup> and human RNA vaccines<sup>29–31</sup> have raised renewed interest in the possibility of long-lasting GCs potentially under conditions of low or absent renewed antigen exposure. Here we demonstrate clearly that GCs can last for at least 191 days in the absence of new antigen, using an experimental system taking advantage of protein immunization, a

12-day slow-delivery immunization strategy, a robust adjuvant and the use of Env probes to identify antigen-specific B<sub>GC</sub> cells. Furthermore, we demonstrate that GCs are remarkably robust and functional for 6 months. B<sub>GC</sub> cells maintain proliferation, SHM and affinity maturation, and long-lasting GCs can produce high autologous tier-2 neutralizing antibody titres, heterologous neutralizing antibody titres and highly somatically mutated circulating Env-specific B<sub>mem</sub> cells to non-Env base epitopes.

A 12- to 14-day slow-delivery immunization regimen can result in substantially greater capture of vaccine antigens by stromal follicular dendritic cells<sup>13</sup>. Observation of GCs for over 6 months indicates that endocytic recycling of immune complexes by follicular dendritic cells<sup>32</sup> can be surprisingly efficient at maintaining proteins in GCs and protecting them from damage. One probable mechanism of slow-delivery enhancement of GCs is improved immune complex formation, due to antigen supply after the start of the antibody response. Given the immunodominance of antibody responses to the non-neutralizing base of the Env trimer after conventional immunizations, and epitope diversification to non-base epitopes in slow-delivery immunizations (Fig. 2g), we speculate that immune complexes with Env under slow-delivery conditions are primarily composed of base-binding antibodies, which shield the base of the Env trimer in GCs and orient the trimers to better demonstrate neutralizing epitopes antipodal to the base, thereby enriching for neutralizing antibody B cells. This is further illustrated by the shift away from base-directed immunodominance in B<sub>mem</sub> cells during the long prime (Fig. 4h). Thus, the improved autologous and heterologous neutralization noted in group 3 monkeys is probably partly owing to the diversity of B cells recruited and partly due to increased affinity maturation from extensive GC responses. These outcomes match our prediction that immunodominance is a major factor that effects neutralizing antibody responses to candidate HIV vaccines, and the immunodominance of non-neutralizing antibody responses can be overcome by recruiting more diverse B cells to GCs and providing those cells with sufficient time for affinity maturation to become competitive as B<sub>mem</sub> cells with non-neutralizing B<sub>mem</sub> cells at the time of booster immunization<sup>1</sup>. It would be of interest to investigate the potential effects of extending the timing between bolus booster immunizations.

The appearance of neutralizing titres in the long-prime group 3 between weeks 20 and 29 after prime is indicative of continued affinity maturation, leading to GC output of new plasma cells that can produce neutralizing antibodies months after the initial immunization. Regarding the kinetics of B cell memory development, our data are inconsistent with a model of predominantly early B<sub>mem</sub> cell production from continuing GCs. If that were the case, median B<sub>mem</sub> cell HC SHMs would be low (for example, two to five mutations), corresponding to early B<sub>GC</sub> cells (3–4 weeks). By contrast, median B<sub>mem</sub> cell HC SHM was 17 at week 36 (Fig. 4g) and less than 15% of B<sub>mem</sub> cells had fewer than 10 mutations. The simplest interpretation of these observations is that early B<sub>mem</sub> cells may re-enter GCs to undergo further SHM and affinity maturation. Our finding of shared B<sub>GC</sub> clones between left and right LNs and circulating B<sub>mem</sub> cells is most consistent with this B<sub>mem</sub> GC re-entry model. In addition, these data are inconsistent with a model of B<sub>GC</sub> cell extinction after around 1 month and dominant replacement by incoming naive B cells, because unmutated B cells were rare in GCs after 1 month (Fig. 4b) and median B<sub>GC</sub> cell SHM levels continued to increase over 6 months. B<sub>GC</sub> cell clonal lineages were also observed to span the full 6 months after priming. Overall, our data are consistent with ongoing production or recycling of B<sub>mem</sub> cells and the production of plasma cells from ongoing GCs over the course of the priming period.

We have shown that GCs can persist for more than 6 months in response to a priming immunization, with several notable outcomes. These findings indicate that patience can have value in allowing antibody diversification and evolution in GCs over extended periods of time, and this long-prime, slow-delivery immunization approach holds promise for difficult vaccine targets.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-022-05216-9>.

- Havenar-Daughton, C., Lee, J. H. & Crotty, S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. *Immunol. Rev.* **275**, 49–61 (2017).
- Lee, J. H. & Crotty, S. HIV vaccinology: 2021 update. *Semin. Immunol.* **51**, 101470 (2021).
- Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. *Annu. Rev. Immunol.* **34**, 635–659 (2016).
- Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. *Sci. Transl. Med.* **11**, eaaz2686 (2019).
- Mesin, L., Ersching, J. & Victora, G. D. Germinal center B cell dynamics. *Immunity* **45**, 471–482 (2016).
- Crotty, S. T. Follicular helper cell biology: a decade of discovery and diseases. *Immunity* **50**, 1132–1148 (2019).
- Victora, G. D. & Nussenzweig, M. C. Germinal centers. *Annu. Rev. Immunol.* **30**, 429–457 (2012).
- Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. *Cell* **177**, 524–540 (2019).
- Gitlin, A. D. et al. T cell help controls the speed of the cell cycle in germinal center B cells. *Science* <https://doi.org/10.1126/science.aac4919> (2015).
- Gitlin, A. D., Shulman, Z. & Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. *Nature* **509**, 637–640 (2014).
- Tam, H. H. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. *Proc. Natl Acad. Sci. USA* **113**, E6639–E6648 (2016).
- Pauthner, M. et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. *Immunity* **46**, 1073–1088 (2017).
- Cirelli, K. M. et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. *Cell* **177**, 1153–1171 (2019).
- Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. *Semin. Immunol.* **39**, 14–21 (2018).
- Steichen, J. M. et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. *Immunity* **45**, 483–496 (2016).
- Silva, M. et al. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. *Sci. Immunol.* **6**, eabf1152 (2021).
- Havenar-Daughton, C. et al. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer. *Cell Rep.* **17**, 2195–2209 (2016).
- Havenar-Daughton, C. et al. Cytokine-independent detection of antigen-specific germinal center T follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique. *J. Immunol.* **197**, 994–1002 (2016).
- Hu, J. K. et al. Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. *J. Virol.* **89**, 10383–10398 (2015).
- Cottrell, C. A. et al. Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. *PLoS Pathog.* **16**, e1008753 (2020).
- Bianchi, M. et al. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. *Immunity* **49**, 288–300.e8 (2018).
- Zhao, F. et al. Mapping neutralizing antibody epitope specificities to an HIV Env trimer in immunized and in infected rhesus macaques. *Cell Rep.* **32**, 108122 (2020).
- Kennedy, D. E. et al. Novel specialized cell state and spatial compartments within the germinal center. *Nat. Immunol.* **21**, 660–670 (2020).
- Holmes, A. B. et al. Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. *J. Exp. Med.* **217**, e20200483 (2020).
- Nowosad, C. R. et al. Tunable dynamics of B cell selection in gut germinal centres. *Nature* **588**, 321–326 (2020).
- Petrovas, C. et al. CD4 T follicular helper cell dynamics during SIV infection. *J. Clin. Invest.* **122**, 3281–3294 (2012).
- Yewdell, W. T. et al. Temporal dynamics of persistent germinal centers and memory B cell differentiation following respiratory virus infection. *Cell Rep.* **37**, 109961 (2021).
- Poon, M. M. L. et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. *Sci. Immunol.* **6**, eabl9105 (2021).
- Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses. *Nature* **596**, 109–113 (2021).
- Lederer, K. et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. *Cell* **185**, 1008–1024 (2022).
- Kim, W. M. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. *Nature* **604**, 141–145 (2022).
- Heesters, B. A. et al. Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. *Immunity* **38**, 1164–1175 (2013).
- Lee, J. H. et al. Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells. *NPJ Vaccines* **6**, 113 (2021).
- deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. *J. Virol.* **88**, 2489–2507 (2014).

35. Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. *J. Immunol. Methods* **409**, 131–146 (2014).
36. Nogal, B. et al. Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines. *Cell Rep.* **30**, 3755–3765 (2020).
37. Lander, G. C. et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. *J. Struct. Biol.* **166**, 95–102 (2009).
38. Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. *eLife* **7**, e42166 (2018).
39. Vázquez Bernat, N. et al. Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles. *Immunity* **54**, 355–366 (2021).
40. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 (2021).
41. Vander Heiden, J. A. et al. PRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. *Bioinformatics* **30**, 1930–1932 (2014).
42. Hsieh, T. C., Ma, K. H. & Chao, A. iNEXT: an R package for rarefaction and extrapolation of species diversity (Hill numbers). *Methods Ecol. Evol.* **7**, 1451–1456 (2016).
43. Hoehn, K. B. et al. Human B cell lineages associated with germinal centers following influenza vaccination are measurably evolving. *eLife* **10**, e70873 (2021).
44. Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at *bioRxiv* <https://doi.org/10.1101/060012> (2021).
45. Sergushichev, A. A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. Preprint at *bioRxiv* <https://doi.org/10.1101/060012> (2016).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© The Author(s), under exclusive licence to Springer Nature Limited 2022, corrected publication 2023

<sup>1</sup>Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA. <sup>2</sup>Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA. <sup>3</sup>IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. <sup>4</sup>Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. <sup>5</sup>Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA. <sup>6</sup>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. <sup>7</sup>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>8</sup>Tulane National Primate Research Center, Tulane School of Medicine, Covington, LA, USA. <sup>9</sup>Emory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. <sup>10</sup>Department of Surgery, Laboratory for AIDS Vaccine Research & Development, Duke University Medical Center, Duke University, Durham, NC, USA. <sup>11</sup>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. <sup>12</sup>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>13</sup>Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>14</sup>Howard Hughes Medical Institute, Chevy Chase, MD, USA. <sup>15</sup>These authors contributed equally: Jeong Hyun Lee, Henry J. Sutton. ✉e-mail: [shane@lji.org](mailto:shane@lji.org)

## Methods

### Protein expression and purification

BG505 MD39 SOSIP Env trimers (MD39) were co-expressed with furin in HEK293F cells and expressed as previously described<sup>15</sup>. Trimers used for immunizations were expressed tag-free and quality checked for low endotoxin levels. BG505 MD39 SOSIP and BG505 MD39-base knockout trimers used as baits in flow cytometry were expressed with a C-terminal Avi-tag and biotinylated using a BirA biotinylation kit according to the manufacturer's instructions (Avidity). The BG505 MD39-base knockout trimer had the following mutations relative to the BG505 MD39 SOSIP: A73C, R500A, P561C, C605T, S613T, Q658T, L660N, A662T and L663C.

Monoclonal antibodies were generated by cloning synthesized Fab variable-region genes into human antibody expression vectors. HCs were expressed as human IgG1. Antibody expression plasmids and recombinantly expressed monoclonal antibodies were produced by Genscript.

### Animals and immunizations

For MD39 plus SMNP escalating-dose immunization groups, Indian rhesus macaques (*Macaca mulatta*) were housed at Alpha Genesis and treated in accordance with protocols approved by the Alpha Genesis Animal Care and Use Committee (IACUC). Two females and two males, matched for age and weight, were assigned to each experimental group. Monkeys were aged 2–3 years at the time of the priming immunization. All immunizations were given subcutaneously in the left and right mid-thigh with a total dose of 50 µg of MD39 and 375 µg of SMNP each side. For priming, a 12-day escalating dose strategy was used (Extended Data Fig. 1a)<sup>13</sup>.

For the MD39 plus alum bolus group, RMs were housed at the Tulane National Primate Research Center as part of a larger NHP study (I.P. et al., manuscript in preparation). This study was approved by the Tulane University IACUC. Animals were grouped together to match age, weight and gender. Animals were aged 3.5–5.0 years at the time of first immunization, with three females and three males in the study group. All immunizations were given subcutaneously in the left and right mid-thigh with 50 µg of MD39 and 500 µg of alum (alhydrogel adjuvant 2%; InvivoGen) per side. All animals were maintained in accordance with NIH guidelines.

### LN FNA

FNAs were used to sample the left and right ILNs and were performed by a veterinarian. Draining LNs were identified by palpation. A 22-gauge needle attached to a 3 ml syringe was passed into the LN up to five times. Samples were placed in RPMI containing 10% (v/v) fetal bovine serum (FBS) and 1× penicillin/streptomycin (pen/strep). Samples were centrifuged, and ammonium chloride-potassium lysing buffer was used if the sample was contaminated with red blood cells. Samples were frozen down and maintained in liquid nitrogen until analysis.

### Flow cytometry and sorting

Frozen FNA or PBMC samples were thawed and recovered in 50% (v/v) FBS in RPMI. Recovered live cells were enumerated and stained with the appropriate staining panel. MD39 and MD39-base knockout baits were prepared by mixing biotinylated MD39 with fluorophore-conjugated streptavidin (SA) in small increments at room temperature (RT) in an appropriate volume of 1× PBS over the course of 45 min. MD39 and streptavidin were added to the cells for 20 min, after which the antibody master mix was added for a further 30 min at 4 °C. Where knockout baits were used, these were first added to the cells for 20 min, then WT MD39 and streptavidin baits and were added for a further 20 min, followed by the addition of the remainder of the staining panel for a further 30 min at 4 °C, similar to a previously described protocol<sup>13</sup>. Fully supplemented RPMI (R10; 10% (v/v) FBS, 1× pen/strep, 1× GlutaMAX) was used as FACS buffer. For sorting, anti-human hashtag antibodies

(BioLegend) were individually added to each sample at a concentration of 2.5 µg per 5 million cells at the time of addition of the master mix. Group 1 samples were sorted on a FACSFusion (BD Biosciences); those from groups 2 and 3 were either acquired or sorted on a FACSymphony S6 (BD Biosciences). Indexed V(D)J, Feature Barcode and GEX libraries of sorted LN FNA samples were prepared according to the protocol for Single Indexed 10X Genomics V(D)J 5' v.1.1, with Feature barcoding kit (10X Genomics). For sorted PBMC samples, Indexed V(D)J, Feature Barcode and GEX libraries were prepared using the Dual Indexed 10X Genomics V(D)J 5' v.2 with Feature barcoding kit (10X Genomics). Custom primers were designed to target RM BCR constant regions. Primer set for PCR 1: forward, AATGATACGGCGACCACCGAGATCTA CACTCTTCCCTACACGACGCTC; reverse, AGGGCACAGCCACATCCT, TTGGTGTGTCTGGGCTT, TGACGTCCTTGAAGCCA, TGTGGGACTTC CACTGGT, TGACTTCGAGGCATAGA. Primer set for PCR 2: forward, AATGATACGGCGACCACCGAGATCT; reverse, TCACGTTGAGTG GCTCCT, AGCCCTGAGGACTGTAGGA, AACGGCCACTTCGTTTGT, ATCTGCCTTCCAGGCCA, ACCTTCCACTTTACGCT. Forward primers were used at a final concentration of 1 µM and reverse primers at 0.5 µM, each per 100 µl of PCR reaction. Libraries were pooled and sequenced on a NovaSeq Sequencer (Illumina) as previously described<sup>33</sup>.

During the long-prime tracking phase (weeks 16–25, right LNs), samples were stained as described above, fixed in BD Cytotfix (BD Biosciences) then analysed on a FACSCelesta (BD Biosciences). For intracellular staining, cells were stained as described above then fixed with the Foxp3/Transcription factor staining kit (Invitrogen). Cells were washed with 1× diluted permeabilization buffer then stained for 1 h with antibodies targeting transcription factors of interest. Cells were washed and analysed on a Cytex Aurora (Cytex Biosciences). All flow cytometry data were analysed in Flowjo v.10 (BD Biosciences).

For LN FNA data inclusion in GC gating, a threshold of 250 B cells in the sample was used and, for Env-binding GC B cell gating, a threshold of 75 GC B cells was used. Any sample with fewer than 75 GC B cells but with a B cell count of more than 500 cells was set to a baseline of 0.001% Env<sup>+</sup> GC B cells (percentage of B); otherwise, the limit of detection was calculated based on the median of (3/(number of B cells collected)) from pre-immunization LN FNA samples. Some group 2 and 3 LN FNA vials had barely detectable cells in the stained samples and were not analysed.

The following reagents were used for staining: Alexa Fluor 647 streptavidin (Invitrogen), BV421 streptavidin (BioLegend), BV711 streptavidin (BioLegend), PE streptavidin (Invitrogen), Live/Dead fixable aqua (Invitrogen), Propidium iodide (Invitrogen), eBioscience Fixable Viability Dye eFluor 780 (Invitrogen), mouse anti-human CD20 BV785, BUV395, Alexa Fluor 488, PerCP-Cy5.5 (2H7, BioLegend), mouse anti-human IgM PerCP-Cy5.5, BV605 (G20-127, BD Biosciences), mouse anti-human CD4 BV650, Alexa Fluor 700 (OKT4, BioLegend), mouse anti-human PD1 BV605 (EH12.2H7, BioLegend), mouse anti-human CD3 BV786, APC-Cy7 (Sp34-2, BD Biosciences), mouse anti-human CXCR5 PE-Cy7 (MUSUBEE, ThermoFisher), mouse anti-human CD71 PE-CF594 and FITC (LO1.1), mouse anti-human CD38 PE, APC (OKT10, NHP Reagents), mouse anti-human CD8a APC-eFluor 780 (RPA-T8, ThermoFisher), mouse anti-human CD14 APC-Cy7 (M5E2, BioLegend), mouse anti-human CD16 APC-Cy7 (3G8, BioLegend), mouse anti-human CD16 APC-eFluor 780 (ebioCD16, Invitrogen), mouse anti-human IgG Alexa Fluor 700, BV510, and BV786 (G18-145, BD Biosciences), mouse anti-NHP CD45 BUV395 (D058-1283, BD Biosciences), mouse anti-human BCL6 Alexa Fluor 647 (K112-91, BD Biosciences), mouse anti-human KI67 BV480 (B56, BD Biosciences), mouse anti-human FoxP3 BB700 (236A/E7, BD Biosciences), mouse anti-human CD27 PE-Cy7 (O323, BioLegend), goat anti-human IgD FITC (polyclonal, Southern Biotech), Armenian hamster anti-mouse/human Helios PE/Dazzle 594 (22F6, BioLegend), TotalSeq-C anti-human Hashtag antibody 1-8 (LNH-94 and 2M2, BioLegend) and TotalSeq-C0953 PE Streptavidin (BioLegend).

## Detection of antigen-specific GC-T<sub>FH</sub> cells

Antigen-induced marker-based identification of Env-specific GC-T<sub>FH</sub> cells was performed as previously described<sup>13,18</sup>. In summary, cells were thawed in 50% (v/v) FBS in RPMI and resuspended in 500 µl of DNase in R10 (100 µl of DNase in 900 µl of R10) for 15 min at 37 °C in a CO<sub>2</sub>- and humidity-controlled incubator, 5 ml of R10 was added and cells were further rested for 3 h. Cells were enumerated and seeded at about 1 million per well in R10, and incubated with a final concentration of 2.5 µg ml<sup>-1</sup> MD39 Env peptide pool, 10 pg ml<sup>-1</sup> staphylococcal enterotoxin or media only (unstimulated) for 18 h at 37 °C in a CO<sub>2</sub>- and humidity-controlled incubator. Mouse anti-human CXCR5 PE-Cy7 (1:100, MU5UBEE; ThermoFisher) was added to each well at the start of stimulation. Cells were washed and stained for 45 min in the dark at 4 °C. After staining, cells were washed and fixed with BD Cytotfix (BD Biosciences) and analysed on a BD FACSCelesta (BD Biosciences). The following antibodies were used in the flow panel: mouse anti-human CD4 Alexa Fluor 700 (OKT4, BioLegend), mouse anti-human CD20 BV785 (2H7, BioLegend), mouse anti-human PD1 BV605 (EH12.2H7, BioLegend), mouse anti-human CXCR5 PE-Cy7 (MU5UBEE, ThermoFisher), mouse anti-human CD134 PE (LI06, BD BioLegend), mouse anti-human 4-1BB APC (4B4-1, BioLegend), mouse anti-human CD25 FITC (BC96, BioLegend), mouse anti-human CD16 APC-eFluor 780 (ebioCD16, Invitrogen), mouse anti-human CD8a APC-eFluor 780 (RPA-T8, ThermoFisher), mouse anti-human CD14 APC-Cy7 (M5E2, BioLegend) and eBioscience Fixable Viability Dye eFluor 780 (Invitrogen).

## Neutralization assays

Pseudovirus neutralization assays at Scripps were performed as previously described<sup>12</sup>. BG505 pseudovirus neutralization was tested using the BG505.W6M.ENV.C2 isolate with the T332N mutation to restore the N332 glycosylation site. Assays were done with duplicate wells per assay and four independent repeats were performed. Heterologous neutralization breadth was tested on a panel of 12 cross-clade isolates, representative of larger virus panels isolated from diverse geography and clades<sup>34</sup>. In some figures virus names are abbreviated as follows: 398-F1\_F6\_20: 398F1; 246-F3\_C10\_2: 246F3; CNE55: not abbreviated; CNE8: not abbreviated; X2278-C2-B6: X2278; TRO.11: not abbreviated; BJOX002000.03.2: BJOX2000; CH119.10: not abbreviated; Ce703010217\_B6: Ce0217; Ce1176\_A3: Ce1176; 25710-2.43: 25710; X1632\_S2\_B10: X1632. Heterologous neutralization breadth assays at Scripps were performed with duplicate wells per assay, and four independent repeats of heterologous neutralization breadth assays. The cut-off for neutralizing serum dilution was set at 1:30 or 1:20 depending on the starting serum dilution. For Fig. 2c,d, an ID<sub>50</sub> of less than or equal to 30 was considered non-neutralizing. Absolute ID<sub>50</sub> values were calculated using normalized relative luminescence units and a customized nonlinear regression model:

$$ID_{50} = \text{Bottom} + \frac{\text{Top} - \text{bottom}}{1 + 10^{(\log(\text{absolute}IC_{50} - x) \times \text{Hill slope} + \log(\frac{\text{top} - \text{bottom}}{50 - \text{bottom}} - 1))}}$$

with the bottom constraint set to 0 and top constraint set to the <100 model in Prism 8 (GraphPad). Pseudovirus neutralization assays at Duke were performed as previously described<sup>35</sup>. Positive controls (monoclonal antibodies) were included for every virus in every assay run and tracked as part of assay quality control, as well as a murine leukemia virus negative control. Duke samples were assayed in duplicate and assays were performed with good clinical laboratory practice compliance.

## ELISA

Plasma samples were thawed, heat inactivated at 56 °C for at least 30 min and spun down. Corning 96-well half-area plates were coated overnight with streptavidin at 2.5 µg ml<sup>-1</sup>. Plates were washed three times with wash buffer (PBS, 0.05% (v/v) Tween-20) then coated with

biotinylated MD39 or MD39-base knockout trimers at 1 µg ml<sup>-1</sup>. After washing three times with wash buffer, plates were blocked with blocking buffer (PBS, 3% (w/v) BSA) for 1 h at RT. Plasma serially diluted in blocking buffer was allowed to bind with trimers for 1 h at RT. Plates were washed three times and incubated with goat anti-rhesus IgG-HRP antibody (Southern Biotech, 1:10,000 in blocking buffer) for 1 h at RT. Plates were washed six times and developed with 1-Step Ultra TMB (ThermoFisher). The reaction was stopped with an equivalent volume of 2N H<sub>2</sub>SO<sub>4</sub> (Ricca Chemical Co.), and the signal was read at optical density 450 nm on an EnVision plate reader (Perkin Elmer). Endpoint titres were interpolated from an Asymmetric Sigmoidal, 5PL X log(concentration) model in Prism 9 (GraphPad).

## Surface plasmon resonance

The interactions of MD39 trimer analytes binding to IgGs captured on the surface plasmon resonance (SPR) sensor chip were assessed. The apparent affinities determined in these experiments do not reflect monovalent Fab-trimer interactions but rather include enhancement of binding due to avidity. Apparent kinetics and affinities of antibody-antigen interactions were measured on a Biacore 8K (Cytiva) using Series S CM5 Sensor Chip (Cytiva) and 1× HBS-EP+ pH 7.4 running buffer (20× stock from Teknova) supplemented with BSA at 1 mg ml<sup>-1</sup>. The Human Antibody Capture Kit was used according to the manufacturer's instructions (GE) to immobilize about 7,000 response units of capture antibody on each flow cell. In a typical experiment, around 300–400 response units of monoclonal antibodies were captured on each flow cell, and trimer analytes were passed over them at 15 µl min<sup>-1</sup> for 2 min followed by 5 min of dissociation time. Regeneration was accomplished using 3 M MgCl<sub>2</sub> with 240 s contact time. The top concentration of the gp140 protomer was 10 µM, with three protomers per trimer. Five analyte concentrations were tested, with fourfold dilution. Raw sensorgrams were analysed using Biacore Insight Evaluation software v.3.0.12.15655 (Cytiva), including blank double referencing, and Kinetic fits with Langmuir model at 1:1 binding stoichiometry were used. Analyte concentrations were measured on a NanoDrop 2000c Spectrophotometer using an absorption signal at 280 nm.

## EMPEM analysis

We performed polyclonal electron microscopy analysis as previously described<sup>21,36</sup>. Plasma antibodies were purified using Protein A Sepharose resin (GE Healthcare), eluted from the resin with 0.1 M glycine at pH 2.5 and buffer exchanged into 1× PBS. Fabs were generated using crystalline papain (Thermo Scientific), digested for 5 h at 37 °C and purified via size exclusion chromatography (SEC) using a Superdex 200 Increase 10/300 column (GE Healthcare). Complexes were assembled with 0.5 mg of polyclonal Fabs incubated overnight with 15 µg of MD39 Env trimers at RT, followed by purification to remove unbound Fab via SEC using a Superose 6 Increase 10/300 column (GE Healthcare). Complexes were diluted to 30–50 µg ml<sup>-1</sup>, immediately placed on 400-mesh Cu grids and stained with 2% (w/v) uranyl formate for 40 s. Images were collected via the Legikon automated imaging interface using either a Tecnai Spirit electron microscope, operated at 120 kV, or a Tecnai TF20 electron microscope, operated at 200 kV; for the former, nominal magnification was ×52,000 with a pixel size of 2.06 Å; the TF20 was operated at a nominal magnification of ×62,000 with a pixel size of 1.77 Å. Micrographs were recorded using a Tietz 4k × 4k TemCam-F416 CMOS camera. Particles were extracted via the Appion data processing package<sup>37</sup> in which roughly 100,000 particles were auto-picked and extracted. Using Relion 3.0 (ref. <sup>38</sup>), particles were two-dimensionally classified into 100 classes and those with antigen-Fab characteristics were selected for three-dimensional (3D) analysis. Initially 3D classification was done using 20–40 classes, with a low-resolution model of a non-liganded HIV Env ectodomain used as reference. Particles from similar-looking classes were combined and reclassified, with a subgroup of 3D classes processed using 3D auto-refinement. UCSF

Chimera 1.13 was used to visualize and segment 3D-refined maps. Quantitation of epitope recognition in Fig. 2h was done by tabulating the number of epitopes recognized among each animal per group and then collation per group (for example, out of a total of six epitope sites  $\times$  4 animals = 24). Epitope sites not recognized per animal were also tabulated, to account for variation in animal group size. Fisher's exact tests were used to test for significant differences in the number of epitopes recognized per group.

### BCR sequencing and processing

A custom RM germline VDJ library was generated using references published previously<sup>13,39</sup>. Cell Ranger v.3.0 was used to assemble full-length V(D)J reads. The constants.py file in the Cell Ranger VDJ python library was modified to increase maximum acceptable CDR3 length to 110 nucleotides. Cell Ranger v.6 was used to obtain gene expression counts from sequenced GEX libraries. Libraries were aligned to the Ensemble Mmul10 reference genome, with the addition of mitochondrial genes from Mmul9. Sequences were de-multiplexed by hashtags using the MULTISEQDemux command in Seurat v.4 (ref. <sup>40</sup>). For HC sequences in which both kappa and lambda light-chain (LC) contigs were detected, the B cell was assigned a lambda LC because lambda LC rearrangement occurs only if the kappa LC is not productive.

### Longitudinal lineage and somatic mutation analysis of BCR sequences

The VDJ sequence output from Cell Ranger was further analysed using packages from the Immcantation portal<sup>41</sup>. An IgBLAST database was built from the custom RM germline VDJ Library and was then used to parse the  $10 \times V(D)J$  output from Cell Ranger into an AIRR community standardized format using the Change-O pipeline, to allow for further downstream analysis with the Immcantation portal. Clonal lineages were determined for each animal with DefineClones.py using the appropriate clustering threshold as determined by the distToNearest command from the SHazaM package in R. Inferred germline V and J sequences from the reference library were added with CreateGermline.py. Because germline D gene sequences and N nucleotide additions cannot be accurately predicted, these were masked from further analysis. Rarefaction analysis for  $Env^+$  samples was conducted using the package iNext R<sup>42</sup> to confirm acceptable sequence coverage (Extended Data Fig. 10g). The total number of mutations (V- and J-genes) for each HC and LC sequence was calculated by counting the number of nucleotide changes between the observed and predicted germline sequences with Shazam's observed mutation command. For analysis of total HC mutations, all productive HC contigs were analysed; for LCs, only contigs paired with HCs were assessed. Sequences in which the VH or VL call aligned to alleles IGHV3-100\*01, IGHV3-100\*01\_S4205, IGHV3-100\*01\_S4375, IGHV3-36\*01\_S5206, IGHV3-36\*01\_S6650, IGHV3-NL\_1I\*01\_S5714, IGHV4-79-a, IGHV4-NL\_1\*01\_S0419, IGLV1-69, IGLV1-ACR\*0 or IGLV2-ABX\*01 were found to have an extremely high degree of substituted nucleotides at all time points compared with their inferred germline sequences, probably because of poor V-gene assignment due to an incomplete V(D)J reference library. These sequences were excluded from further analysis. Only clones that contained paired HC-LC BCR sequences were analysed when building clonal trees. Maximum-likelihood lineage trees were built for clonal families with Dowser<sup>43</sup> using the pml method in the GetTrees function. For lineage trees, branch length represents the estimated number of total mutations that occurred in each HC sequence and its most recent common ancestor in lineage, rather than a simple count of nucleotide changes in the germline sequence. Strict criteria for identification of clonal lineages that could be found in both left and right LNs included the following requirements: H-CDR3 length greater than 14, multiple N additions in H-CDR3, greater than 20 cells in total and a matching LC within the lineage. A more lenient set of criteria was also used consisting of the following

requirements: H-CDR3 length greater than 10, more than five cells in total and a matching LC within the lineage.

### Diversity analysis

Chao1 estimation of clonal richness was calculated using the iNext R<sup>42</sup> package according to the following formula:

$$S_{\text{Chao1}} = S_{\text{obs}} + \frac{F_1(F_1 - 1)}{2(F_2 + 1)}$$

where  $S_{\text{obs}}$  is the total number of observed species and  $F_1$  and  $F_2$  are the numbers of singletons and doubletons, respectively. Simpson diversity indices were computed using the alphaDiversity function from Alakazam, with uniform resampling down to 50 for LN FNA samples and 25 for PBMC samples to correct for sequencing depth, at diversity order ( $q$ ) = 2. FNA samples containing fewer than 50 cells and PBMC samples containing fewer than 25 cells were excluded from diversity analysis. Simpson diversity ( $D$ ) was calculated using the inverse Simpson index formula where  $R$  is richness (the total number of unique lineages in sample) and  $P_i$  is the proportional abundance of the  $i$ th lineage:

$$D_2 = \frac{1}{\sum_{i=1}^R p_i^2}$$

### Transcriptomics analysis

The package Seurat v.4 (ref. <sup>40</sup>) was used for graph-based clustering and visualization of the gene expression data generated by Cell Ranger. Initial filtering was conducted on each sample to remove cells expressing fewer than 200 or more than 4,500 genes, as well as those with less than 10% of their transcriptome comprising mitochondrial DNA. Gene expression counts were log normalized via the NormalizeData command. A list of common variable genes across all samples was identified with the function SelectIntegrationFeatures. Expression of these common variable genes was scaled using principal component analysis (PCA) conducted with RunPCA. Next, all samples were integrated into a single dataset using a reciprocal PCA reduction to remove batch effects via the commands FindIntegrationAnchors and IntegrateData. Louvain clustering was conducted on the entire integrated dataset with the functions FindNeighbours and FindCluster. Clusters containing large numbers of cells with high levels of mtDNA, as well as those with low *MS4AI* (CD20) and *CD19* expression, were excluded from further analysis. Differentially expressed genes were identified in Seurat with the function FindMarkers by running a Wilcoxon rank-sum test for each cluster against all other clusters. Gene set enrichment analysis (GSEA) was conducted using the package fgsea in R<sup>44,45</sup>. Differentially expressed genes from previously identified human light-zone, dark-zone, intermediate,  $B_{\text{mem}}$  and plasma cell subsets were previously described<sup>24</sup> and combined to create the gene sets used for GSEA. LZ1 and DZ5 were selected as representative light-zone and dark-zone clusters, respectively, based on GSEA scores.

### Graphs, statistics and cell generation calculation

All statistics were calculated in Prism 9 or R unless stated otherwise. The statistical tests used are indicated in the respective figure legends and incorporated a two-tailed test. All graphs were generated in Prism 9 or R. Geometric mean and geometric s.d. are shown for data plotted on a  $\log_{10}$  axis; mean and s.d. are plotted for data graphed on a linear axis. Median and quartiles 1 and 3 are shown for violin plots. UMAP plots were generated using Seurat v.4 (ref. <sup>40</sup>). For comparison of total HC and LC mutations between groups 2 and 3, statistical significance was calculated only if mean mutations were significantly different according to per-animal comparisons. Extra statistical test information is provided in the individual Methods experimental approach sections. All Mann-Whitney tests are two-sided.  $P$  values are defined throughout as follows: not significant,  $P > 0.05$ ; \* $P \leq 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P \leq 0.0001$ .

# Article

## Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

Gene Expression data generated in the current study are available in the Gene Expression Omnibus database under accession code GSE209904. BCR sequencing data are available in the SRA under accession code PRJNA861839. 3D EM reconstructions are available from the Electron Microscopy Data Bank under the following EMD codes: EMD-27600–27605, EMD-27607–27612 and EMD-27614–27615. Sequencing data and electron microscopy particle stacks are available on request. Source data are provided with this paper.

**Acknowledgements** We thank C. Kim and the Flow Cytometry Core at La Jolla Institute for Immunology (LJI) and the LJI Sequencing Core. We also thank G. Karlsson Hedestam and M. Corcoran from the Karolinska Institutet for provision of additional naive RM IGHV reference sequences before publication. This study was partly performed at AlphaGenesis, Inc. This work was supported in part by the National Institute of Allergy and Infectious Diseases of the NIH under award nos. CHAVI-ID UM1AI100663, CHAVD UM1AI144462, R01 AI125068, R01 AI136621 and P01AI048240; NIH NIAID SVEU contract no. HHSN272201300004; and NIH NIAID NHP-CIL (contract nos. HHSN272201700022C and P51OD011104). This work was also

supported by the Bill and Melinda Gates Foundation (no. BMGF OPP1203211) and the Collaboration of AIDS Vaccine Discovery (no. OPP1115782/INV-002916).

**Author contributions** J.H.L. and S.C. conceived and designed experiments. D.J.I. provided conceptual insights and SMNP. J.H.L. performed and analysed most experiments pertaining to group 2 and 3 LN FNA data, generated FNA BCR sequencing data and assisted with FNA BCR sequencing analysis. H.J.S. analysed BCR data, performed all experiments related to PBMC samples and generated and analysed single-cell transcriptomics data. J.H.L. and C.K. performed serum ELISA. R.N. and L.H. performed neutralization assays and analysis. X.S. and D.C.M. performed independent confirmation neutralization assays and analysis. S.T.R., L.M.S., J.L.T., W.-H.L. and G.O. generated and analysed EMPM data. D.J.I. and M.S. supplied the SMNP adjuvant. A.L., C.A.C. and O.K. performed SPR experiments and analysis. C.A.C., E.G., M.K., S.H., T.-M.M., Y.A. and W.R.S. supplied immunogens and flow cytometry baits. C.A.C. and K.M.C. designed primers. I.P., A.K., C.A., M.F., B.F.G., J.P.D., F.S., P.P.A. and R.S.V. performed Env trimer plus alum rhesus studies. D.G.C. and G.S. provided technical guidance for studies performed at the Tulane National Primate Research Center. A.B.W. and D.R.B. provided supervision. J.H.L. and S.C. wrote the original draft. H.J.S. and L.H. contributed to figure generation. H.J.S., D.R.B., D.J.I., A.B.W. and W.R.S. provided comments and assisted with revision.

**Competing interests** W.R.S. has a patent related to the MD39 immunogen (US patent no. 11,203,617). M.S., D.J.I. and S.C. have patent related to the SMNP adjuvant.


## Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-022-05216-9>.

**Correspondence and requests for materials** should be addressed to Shane Crotty.


**Peer review information** *Nature* thanks the anonymous reviewers for their contribution to the peer review of this work.

**Reprints and permissions information** is available at <http://www.nature.com/reprints>.



**Extended Data Fig. 1 | Escalating dose immunization strategy and representative flow cytometry analysis of FNA samples. a,** Priming escalating dose strategy and injection schedule. **b,** Gating strategy for the longitudinal analysis of GC-T<sub>FH</sub> and B<sub>GC</sub> cells from ILN FNA samples of Groups 2


and 3 animals. CD71<sup>+</sup>CD38<sup>-</sup>/MD39<sup>+/+</sup> cells were sorted for BCR sequencing and transcriptomic analyses. CD71<sup>+</sup>CD38<sup>-</sup>/MD39<sup>neg/neg</sup> cells were also sorted for weeks 3,4,7, and 10. **c,** Gating strategy for the longitudinal analysis B<sub>GC</sub> cells from ILN FNA samples of Group1 animals.



Extended Data Fig. 2 | See next page for caption.


**Extended Data Fig. 2 | B<sub>GC</sub> and GC-T<sub>FH</sub> kinetics.** **a**, Env-binding B<sub>GC</sub> cells as a percent of total CD20<sup>+</sup> B cells. **b**, Env-binding B<sub>GC</sub> cells as a percent of total B<sub>GC</sub> cells. **c**, Ratio of PE geometric mean fluorescent intensity (gMFI) of MD39<sup>+/+</sup> B<sub>GC</sub> cells to MD39<sup>neg/neg</sup> B<sub>GC</sub> cells calculated for Group 2 and 3 FNA samples at post prime time points. MD39<sup>+/+</sup> (green gate) and MD39<sup>neg/neg</sup> B<sub>GC</sub> (magenta gate) gating is shown in Extended Data Fig. 1b. Data from only the LLN were analyzed for week 19-25 samples, since the RLN samples for these time points were analyzed on a different flow cytometer during the tracking period. **d**, Kinetics of GC-T<sub>FH</sub> cells for Group 2 & 3 animals. Gating strategy is shown in Extended Data Fig. 1b. **e**, Representative flow plot of an AIM assay to detect Env-specific GC-T<sub>FH</sub> cells after 18 hrs of ex vivo restimulation. Stimulation conditions: 15-mer

overlapping Env peptide megapool (Env MP), staphylococcal enterotoxin (SEB), or unstimulated (unstim.). **f**, Env-specific GC-T<sub>FH</sub> cells (CXCR5<sup>hi</sup>PD-1<sup>hi</sup>, gated on FSC-A/SSC-A, FSC-H/FSC-W, SSC-H/SSC-W, Live/Dead Fixable e780<sup>-</sup>, CD4 AF700<sup>+</sup>B220 BV785<sup>-</sup>) detected at 6 wks post boost (Group 2: week 16, Group 3: week 36) quantified by AIM assay using the indicated pair of activation markers, or positive for any two of the three AIM markers (Or gates). Data shown is background (AIM<sup>+</sup> signal from unstimulated samples) subtracted. Left and right ILNs are graphed as independent data points. Mean and SD or geometric mean and geometric SD are plotted depending on the scale. Limit of detection (LOD). Mann-Whitney test performed.




**Extended Data Fig. 3 | ED immunization using SMNP improves the quality of Env-specific antibody responses.** **a**, Group 1 autologous neutralization titers determined by assays performed by two independent labs (Scripps Research Institute [Scripps] or Duke) for week 12.  $ID_{50} < 20$  is considered non-neutralizing (NN). **b**, Week 3 post-boost Group 2 and 3 serum neutralization  $ID_{50}$  titers determined independently from a second laboratory (Duke). NN:  $ID_{50} < 20$ . <sup>†</sup>Viruses for which serum neutralization was not determined for Group 3 animal DHHT due to limited serum availability. **c**, Number of heterologous tier-2 viruses neutralized out of 11 tested in (b). <sup>†</sup>Neutralization for only 6 viruses was

tested for DHHT. **d-e**, Serum neutralization assays (Scripps) tested head-to-head with data shown in Fig. 2e using week 3 post-boost 2 sera from four RMs escalating-dose immunized with an ISCOM adjuvant (SMNP without MPLA) and BG505 Env (d)<sup>12</sup>, and week 2 post-boost 2 sera from six RMs bolus immunized with SMNP and MD39 Env (e)<sup>15</sup>. NN:  $ID_{50} < 30$ . **f**, Number of tier-2 heterologous viruses neutralized by post-boost 2 serum tested in d-e<sup>12,15</sup>. **g**, Number of tier-2 heterologous viruses neutralized with the indicated serum GMT titers (Scripps). **h**, Median tier-2 heterologous neutralization GMT across the 12-virus panel (Scripps).




**Extended Data Fig. 4 | EMPEM analysis of polyclonal antibodies.**  
**a–c**, negatively stained EM micrographs of MD39 Env trimer: polyclonal Fab complexes (top), and 2D-class averages (bottom). Data for RMs in Group 1 (a),

Group 2 (b), and Group 3 (c). The scale bar shown in the lower left corner of each micrograph corresponds to 200 nm. **d**, Electron microscopy data bank (EMDB) codes corresponding to each map generated from EMPEM analysis.




**Extended Data Fig. 5 | Intracellular staining of B<sub>GC</sub> markers. a**, Some left ILN samples were pooled for the intracellular staining panel, for higher cell numbers. **b**, Representative flow plot and complete gating strategy for BCL6 and KI67 staining.



**Extended Data Fig. 6 | Single cell transcriptional profiling of B cells.**


**a**, Single cell transcripts of LN FNA B<sub>GC</sub> (Group 2 and 3 weeks 3, 4, 7, 10 and 16, Group 2 week 13, Group 3 weeks 29 and 33) and PBMC B<sub>mem</sub> cells (Group 2 week 16, Group 3 week 36) were assessed. **b**, A summary of the results from GSEA of upregulated gene profiles from single cell clusters using previously identified

B cell subset gene signatures<sup>24</sup>. Size of the dots represent the normalized enrichment score (NES). Significant NES results are shown in blue, nonsignificant results in red. **c**, Expression levels of the displayed genes used to help identify clusters of B cell subsets. **d**, Relative gene expression of *MKI67*, *AICDA*, *MYC*, *CD40* in combined DZ and LZ clusters.




**Extended Data Fig. 7 | BCR sequences of  $B_{Gc}$  and  $B_{mem}$  cells. a–b**, Number of nucleotide (NT) mutations in the V and J-gene region of LC sequences (Kappa: LC  $\kappa$ , Lambda: LC  $\lambda$ ) derived from Env-specific  $B_{Gc}$  cells after priming. Spaghetti plots track the number of mutations in each animal. **c**, Number of HC mutations at week 6 post-boost. **d**, Number of LC  $\kappa$  and LC  $\lambda$  nucleotide mutations in  $B_{Gc}$  cells, respectively. There are two outliers among Group 3 week 3 LC  $\kappa$  sequences, each with 108 and 105 mutations. **e**,  $B_{Gc}$  cell pre-boost clonal richness. Pre-boost; week 10 and 29 for Group 2 & 3 respectively (Chao1). **f**,  $B_{Gc}$

population diversity at post-prime time points (Simpson's diversity). **g**,  $B_{Gc}$  cell pre-boost population diversity. Pre-boost; week 10 and 29 for Group 2 & 3 respectively (Simpson's diversity). **h**, Gating strategy for the detection of Env-specific  $B_{mem}$  cells. **i**, Diversity of  $B_{mem}$  cells after boosting. Post-boost; week 16 and 36 for Group 2 & 3 respectively (Simpson's diversity). **j**, Number of LC  $\kappa$  and LC  $\lambda$  nucleotide mutations in wk 6 post-boost  $B_{mem}$  cells. Mann-Whitney tests are performed.




**Extended Data Fig. 8 | Examples of BCR clonal lineages with increasing affinities.** **a**, Clonal lineages shown in Fig. 4j, k, observing clones over different LN FNA and PBMC sampling periods, represented as linear phylogenetic trees. MD39 Env binding  $K_D$ s (M) were evaluated by surface plasmon resonance (SPR) for select monoclonal antibodies indicated by the black arrows. HC-UCA in

clone 29121 refers to the HC having an identical AA sequence to the UCA. **b**, Linear phylogenetic trees shown in (a) labeled by Env-binding by flow cytometry. These phylogenies are also shown as circle plots in Fig. 4j. The grey dotted lines indicate 5 estimated HC nucleotide mutations from the most recent common ancestor.



**Extended Data Fig. 9 | Additional examples of longitudinally assessed BCR clonal lineages.** **a**, Example of a clonal lineage observed over multiple different LN FNA and PBMC sampling time points. Clone 29431 has a 9 AA H-CDR3, contains >2N additions and <10 cells per LN (This clone was excluded from LN migration quantitation as it did not meet either the stringent or relaxed H-CDR3 length criteria). **b**, Another clonal lineage observed over different LN FNA and PBMC sampling time points. Clone 6911 has an 11 AA H-CDR3, contains >2N additions and >10 cells per LN. In (a) and (b), each B cell is labeled according to

observed time point (left column), Env-binding by flow cytometry (center column), and sampling location (right column). Each ring indicates 5 estimated HC nucleotide mutations from the most recent common ancestor. **c-d**, Pearson correlation calculated between number of estimated HC nucleotide mutations gained from the most recent common ancestor, and time post-prime. Correlation coefficients are calculated for clones 21094 (c) and 29121 (d) shown in Fig. 4j.



Extended Data Fig. 10 | See next page for caption.

# Article

## Extended Data Fig. 10 | Examples of clonal lineages with unique features.

**a**, A clonal lineage where a substantial fraction of early  $B_{GC}$  cells did not bind Env trimer by flow cytometry. Clone 5491: H-CDR3 15 AAs in length, >2 N additions, found in one LN. **b**, Another clonal lineage with a substantial fraction of  $B_{GC}$  cells that did not detectable bind Env trimer by flow cytometry. Clone 29183: H-CDR3 8 AA in length, >2 N additions, >10 cells per LN. This clone was excluded from LN migration quantitation analysis as it did not meet the required H-CDR3 length criteria. **c**, An example of a clonal lineage that was almost exclusively IgM. Clone 29183: H-CDR3 14 AA in length, >2 N additions, >10 cells per LN. In (a), (b) and (c), each B cell is labeled according to observed time point (left column), Env-binding by flow cytometry (center column), and anatomical sampling location (right column). **d**, Lineage tree 21094 shown in Fig. 4j by anatomical sampling location. Clone 21094: H-CDR3 14 AAs in length, >2 N additions, >10 cells per LN. **e**, Lineage tree 29121 shown in Fig. 4j by sampling location. Clone

29121: H-CDR3 18 AAs in length, >2 N additions, found in one LN. **f**, H-CDR3 length distribution of clones found in one or both ILNs using a broader definition of clonal lineages (H-CDR3 length > 10 AA, > 5 cells in lineage). Lineages found in a single LN and two distal LNs exhibited similar H-CDR3 length distributions. One hypothetical concern about the definition of clonality was the possibility of two independent naïve B cells having identical H-CDR3 and L-CDR3 recombination events. If that were the driving phenomenon behind the observation of matching  $B_{GC}$  cells in distant LNs, based on recombination event likelihoods it would be expected that length distributions would be skewed towards shorter lengths and no N-additions would be observed. **g**, iNext<sup>42</sup> plots showing the results of rarefaction analysis to determine the extent of sequence coverage from the Env<sup>+/+</sup> LN FNA and PBMC VDJ sequence data.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

RNA-seq data will be deposited in the Gene Expression Omnibus database, BCR sequences will be deposited in Genbank, and 3D EM reconstructions are deposited into the Electron Microscopy Data Bank. Sequencing data and EM particle stacks can be provided upon request.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size was based on the availability of Rhesus Macaques. We chose at least 4 animals for all groups to be able to obtain statistical significance upon data analysis. Where available, data points from left and right ILNs from each animal were considered as two separate data points.
Data exclusions	There were little or no cells in some of the LN FNA samples, as LN FNAs typically aspirate a small number of cells. Data were excluded for these samples because there were barely any cells available for assessment by flow cytometry. For samples with small but detectable number of cells, samples were excluded if <250 B cells and <75 GC B cells (for B cell analysis), and <250 CD4 T cells (for GC Tfh analysis) in the sample. For diversity analysis, to conduct uniform re-sampling, FNA samples containing less than 50 cells and PBMC samples containing less than 25 cells were excluded. In autologous pseudovirus neutralization assays, pre-boost data points from 200903 assays (the very first assay performed) were excluded from analysis, because the serum titration was started from 1:102 instead of 1:10 ~ 1:30 (all other assays). Thus, for this replicate only post-boost data points were analyzed, since neutralization ID50 titers would likely be >102.
Replication	Rhesus macaque immunizations were not repeated due to difficulty in having access to a large number of NHPs. To compare serological outcomes compared to our previous NHP studies testing similar immunogens and adjuvants, we repeated neutralization assays with the previous samples along with the current experiment samples for direct comparison of serum neutralization potency. Some neutralization assays were also performed independently by two distinct laboratories to confirm reproducibility.
Randomization	Rhesus macaques were weight and age matched, and randomly divided into Groups 2 and 3 such that there were an even number of female and male macaques in each group. Group 1 animals were housed and immunized at a different facility than Groups 2 and 3 as a part of a separate larger study, but animal groups in that study were assigned according to the same criteria as above.
Blinding	Investigators were not blinded. By the design of the experiment, we could not blind Group 3 because the LNs had to be longitudinally monitored prior to the study endpoint.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

### Methods

n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines	<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern		

## Antibodies

Antibodies used	Alexa Fluor 647 SA (Invitrogen), BV421 SA (Biolegend), BV711 SA (Biolegend), PE SA (Invitrogen), Live/Dead fixable aqua (Invitrogen), Propidium iodide (Invitrogen), eBioscience Fixable Viability Dye eFluor 780 (Invitrogen), mouse anti-human CD20 BV785, BUV395, Alexa Fluor 488, PerCP-Cy5.5 (2H7, Biolegend), mouse anti-human IgM PerCP-Cy5.5, BV605 (G20-127, BD Biosciences), mouse anti-human CD4 BV650, Alexa Fluor 700 (OKT4, Biolegend), mouse anti-human PD1 BV605 (EH12.2H7, Biolegend), mouse anti-human CD3 BV786, APC-Cy7 (Sp34-2, BD Biosciences), mouse anti-human CXCR5 PE-Cy7 (MU5UBEE, ThermoFisher), mouse anti-human CD71 PE-CF594 and FITC (LO1.1), mouse anti-human CD38 PE, APC (OKT10, NHP Reagents), mouse anti-human CD8a APC eFluor 780 (RPA-T8, ThermoFisher), mouse anti-human CD14 APC-Cy7 (M5E2, Biolegend), mouse anti-human CD16 APC-Cy7 (3G8, Biolegend), mouse anti-human CD16 APC-eFluor 780 (ebioCD16, Invitrogen), mouse anti-human IgG Alexa Fluor 700, BV510, and BV786 (G18-145, BD Biosciences), Mouse anti-NHP CD45 BUV395 (D058-1283, BD Biosciences), mouse anti-human BCL6 Alexa Fluor 647 (K112-91, BD Biosciences), mouse anti-human Ki67 BV480 (B56, BD Biosciences), mouse anti-human FoxP3 BB700 (236A/E7, BD Biosciences), mouse anti-human CD27 PE-Cy7 (O323, Biolegend), goat anti-human IgD FITC (polyclonal, Southern Biotech), Armenian
-----------------	---

hamster anti-mouse/human Helios PE/Dazzle 594 (22F6, Biolegend), TotalSeq-C anti-human Hashtag antibody 1-8 (LNH-94 and 2M2, Biolegend), TotalSeq-C0953 PE Streptavidin (Biolegend), mouse anti-human CD134 PE (L106, BD Biolegend), mouse anti-human 4-1BB APC (4B4-1, Biolegend), mouse anti-human CD25 FITC (BC96, Biolegend).

Validation

Validation can be found in the respective manufacturer website or our previous NHP studies (Cirelli et al. Cell 2019, Pauther et al. Immunity 2017, Reiss et al. Plos One 2017).

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

Human (HEK293F).

Authentication

The HEK293F cell line is authenticated by the commercial supplier (ThermoFisher).

Mycoplasma contamination

Cell lines were not tested for Mycoplasma contamination

Commonly misidentified lines  
(See [ICLAC](#) register)

*Name any commonly misidentified cell lines used in the study and provide a rationale for their use.*

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

Indian rhesus macaques (*Macaca mulatta*), 10 females, 10 males, age 2-3 (Groups 2-3) and age 3.5-5 (Group 1).

Wild animals

The study did not involve wild animals.

Field-collected samples

The study did not involve samples collected from the field.

Ethics oversight

The study was approved by the AlphaGenesis Inc. IACUC (Groups 2 and 3), and by the Tulane university IACUC (Group 1).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation

LN FNAs were used to sample the left and right inguinal LNs and were performed by a veterinarian. Draining lymph nodes were identified by palpation. A 22-gauge needle attached to a 3 cc syringe was passed into the LN up to 5 times. Samples were placed into RPMI containing 10% fetal bovine serum, 1X penicillin/streptomycin (pen/strep) (R10). Samples were centrifuged and Ammonium-Chloride-Potassium (ACK) lysing buffer was used if the sample was contaminated with red blood cells. Samples were frozen down in 90% FBS, 10%DMSO and kept in liquid nitrogen. For analysis, each vial of cells was thawed in 10 mL 50% RPMI, 50% DMSO. Cells were spun down and washed an additional time with R10. In the meanwhile, MD39 and MD39-base knockout (KO) baits were prepared by mixing biotinylated MD39 with fluorophore-conjugated streptavidin (SA) in small increments, letting the bait:SA complex form over a total of 45 min at RT in the dark. Prepared cells were first stained with baits for 20 min at 4C. Where a KO bait was used, the KO bait was added first for 20 min, followed by the WT baits for an additional 20 minutes. Without washing, the antibody master mix and relevant Totalseq-C hashtag antibody was added for an additional 30 minutes at 4C. Finally, cells were washed twice with R10 and kept on ice until sorting. For samples that were not sorted, cells were fixed and stored at 4C in the dark until acquisition.

Instrument

BD FACSymphony S6 was used for sorting. BD FACSymphony S6, BD FACSCelesta or Cytek Aurora were used for analysis only.

Software

BD FACSDiva was used for data acquisition from all BD machines. SpectroFlo was used to acquire data from the Cytek Aurora. Flowjo V10 was used for all data analysis.

Cell population abundance

Information regarding cell abundance can be found in Fig. 1b-c, Extended data Fig. 2a-b, where the frequencies of Env-specific GC B cells is graphed.

Gating strategy

All complete gating strategies can be found in the Extended data (Extended data Fig. 1b-c, 2e, 5b, 7h).

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.